Zkusit zdarma
AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTX
Cena:
$ 4.85
-0.04 (-0.82%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

16:01 11-05-2026

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar...

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

7:00 31-03-2026

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

16:00 17-03-2026

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar...

AN2 Therapeutics Stock Cools Off After 90% Rally

AN2 Therapeutics Stock Cools Off After 90% Rally

9:52 11-03-2026

AN2 Therapeutics Inc. (NASDAQ: ANTX) shares were down during Wednesday's premarket session in a vola...

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

14:49 09-03-2026

AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the clinical-stage bio...

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics Announces $40 Million Private Placement Financing

7:00 09-03-2026

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar...

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

7:00 12-01-2026

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

13:00 09-01-2026

AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is...

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

7:00 12-08-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar...

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

7:00 23-07-2025

MENLO PARK, Calif. & GENEVA--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-prof...

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

7:00 30-06-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar...

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

7:00 29-05-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

16:01 13-05-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

16:00 25-03-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Participate at Upcoming Investor Conferences

7:00 20-02-2025

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Participate at Upcoming Investor Conferences

7:00 14-11-2024

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

16:00 13-11-2024

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

7:00 17-10-2024

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp...

3 Penny Stocks To Buy With Just $750

3 Penny Stocks To Buy With Just $750

10:36 24-09-2024

Anyone with any experience as an investor knows that while penny stocks can produce strong returns, ...

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

11:30 19-08-2024

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung ...

close

AN2 THERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH 90-PATIENT INVESTIGATOR-INITIATED TRIAL (IIT) OF EPETRABOROLE IN PATIENTS WITH M. ABSCESSUS LUNG DISEASE

12-01-2026
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

12-11-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)

10-11-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS TO PARTICIPATE IN FIRESIDE CHAT AT EVERCORE HEALTHCONX CONFERENCE

06-11-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS COMMENCES FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL AN2-502998 FOR CHAGAS DISEASE

12-08-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

AN2 THERAPEUTICS AND DNDI COLLABORATE ON CLINICAL DEVELOPMENT OF PROMISING NEW ORAL COMPOUND TO TREAT CHRONIC CHAGAS DISEASE

23-07-2025
MENLO PARK, CALIF. & GENEVA--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX) AND THE NON-PROF...
Více zde

AN2 THERAPEUTICS REPORTS KEY INSIGHTS FROM 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELIOIDOSIS, LAYING GROUNDWORK FOR PHASE 2 PROOF-OF-CONCEPT TRIAL OF EPETRABOROLE

30-06-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

AN2 THERAPEUTICS ANNOUNCES POSTER PRESENTATION HIGHLIGHTING M. ABSCESSUS DATA AT 2025 COLORADO MYCOBACTERIA CONFERENCE

29-05-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

13-05-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

25-03-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS TO PRESENT AT LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE

03-03-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

20-02-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

29-01-2025
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

14-11-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS, PROVIDES IMPORTANT EBO-301 UPDATE AND HIGHLIGHTS PROGRESS ACROSS BORON CHEMISTRY PIPELINE

13-11-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS RECEIVES CONTINUATION GRANT TO DISCOVER NOVEL BORON BASED THERAPIES FOR TUBERCULOSIS (CAUSED BY MYCOBACTERIUM TUBERCULOSIS) AND MALARIA

17-10-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS PROVIDES UPDATE ON EBO-301 PHASE 2/3 STUDY EVALUATING EPETRABOROLE FOR TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE

08-08-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...
Více zde

AN2 THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

14-05-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

AN2 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

28-03-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF AN2 THERAPEUTICS, INC. - ANTX

11-03-2024
NEW YORK , MARCH 11, 2024 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde

LEVI & KORSINSKY, LLP INVESTIGATES POSSIBLE SECURITIES FRAUD VIOLATIONS BY AN2 THERAPEUTICS, INC. (ANTX)

05-03-2024
NEW YORK, NY / ACCESSWIRE / MARCH 5, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCE...
Více zde

ANTX ALERT: LEVI & KORSINSKY, LLP REMINDS INVESTORS OF AN INVESTIGATION INVOLVING POSSIBLE SECURITIES FRAUD VIOLATIONS BY AN2 THERAPEUTICS, INC.

05-03-2024
NEW YORK, NY / ACCESSWIRE / MARCH 5, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCE...
Více zde

SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF AN2 THERAPEUTICS, INC. - ANTX

03-03-2024
NEW YORK , MARCH 3, 2024 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

AN2 THERAPEUTICS, INC. INVESTIGATED BY SHAREHOLDER RIGHTS ADVOCATES - INVESTORS SHOULD CONTACT LEVI & KORSINSKY REGARDING POTENTIAL SECURITIES LAW VIOLATIONS - ANTX

28-02-2024
NEW YORK, NY / ACCESSWIRE / FEBRUARY 28, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMM...
Více zde

AN2 THERAPEUTICS, INC. INVESTIGATION ONGOING: CONTACT LEVI & KORSINSKY ABOUT POTENTIAL SECURITIES FRAUD ALLEGATIONS - ANTX

27-02-2024
NEW YORK, NY / ACCESSWIRE / FEBRUARY 27, 2024 / LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMM...
Více zde

SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF AN2 THERAPEUTICS, INC. - ANTX

24-02-2024
NEW YORK , FEB. 24, 2024 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF AN2 THERAPEUTICS, INC. - ANTX

15-02-2024
NEW YORK , FEB. 15, 2024 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST AN2 THERAPEUTICS, INC. AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM

13-02-2024
LOS ANGELES, CA / ACCESSWIRE / FEBRUARY 13, 2024 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHT...
Více zde

AN2 TO VOLUNTARILY PAUSE ENROLLMENT IN PHASE 3 PART OF PHASE 2/3 PIVOTAL CLINICAL TRIAL EVALUATING EPETRABOROLE FOR TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE

12-02-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

AN2 THERAPEUTICS TO PRESENT AT OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

30-01-2024
MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHAR...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-29 00:00:008-KStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-12 00:00:0010-QStáhnout
2025-08-12 01:00:008-KStáhnout
2025-08-12 01:00:0010-QStáhnout
2025-08-12 00:00:008-KStáhnout
2025-08-12 00:00:0010-QStáhnout
2025-06-20 01:00:008-KStáhnout
2025-06-20 00:00:008-KStáhnout
2025-06-11 01:00:008-KStáhnout
2025-06-11 00:00:008-KStáhnout
2025-05-27 01:00:008-KStáhnout
2025-05-27 00:00:008-KStáhnout
2025-05-13 01:00:008-KStáhnout
2025-05-13 01:00:0010-QStáhnout
2025-05-13 00:00:008-KStáhnout
2025-05-13 00:00:0010-QStáhnout
2025-05-01 01:00:008-KStáhnout
2025-05-01 00:00:008-KStáhnout
2025-03-25 00:00:008-KStáhnout
2025-03-25 00:00:0010-KStáhnout
2025-03-24 23:00:008-KStáhnout
2025-03-24 23:00:0010-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-13 00:00:0010-QStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-12 23:00:0010-QStáhnout
2024-11-05 00:00:008-KStáhnout
2024-11-04 23:00:008-KStáhnout
2024-08-19 01:00:008-KStáhnout
2024-08-19 00:00:008-KStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 01:00:0010-QStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-13 00:00:0010-QStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 00:00:008-KStáhnout
2024-06-24 01:00:008-KStáhnout
2024-06-24 00:00:008-KStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 01:00:0010-QStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-14 00:00:0010-QStáhnout
2024-03-29 00:00:0010-KStáhnout
2024-03-28 23:00:0010-KStáhnout
2024-03-28 00:00:008-KStáhnout
2024-03-27 23:00:008-KStáhnout
2024-02-12 00:00:008-KStáhnout
2024-02-11 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-09-13 01:00:008-KStáhnout
2023-09-13 00:00:008-KStáhnout
2023-09-08 01:00:008-KStáhnout
2023-09-08 00:00:008-KStáhnout
2023-08-16 01:00:008-KStáhnout
2023-08-16 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-06-09 01:00:008-KStáhnout
2023-06-09 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-29 01:00:008-KStáhnout
2023-03-29 01:00:0010-KStáhnout
2023-03-29 00:00:008-KStáhnout
2023-03-29 00:00:0010-KStáhnout
2022-11-09 00:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:008-KStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-10-06 01:00:008-KStáhnout
2022-10-06 00:00:008-KStáhnout
2022-08-11 01:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:008-KStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-06-29 01:00:008-KStáhnout
2022-06-29 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 00:00:008-KStáhnout
preloader